JPRN-jRCT2080221365未知1 期
A phase I open-label, non-randomized, dose-finding safety, tolerance and pharmacokinetic study of TSU-68 in combination with S-1 and oxaliplatin in patients with metastatic colorectal cancer.
适应症
试验速览
- 阶段
- 1 期
- 入组人数
- 15
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 18age old 至 <= 75age old（—）
- 性别
- All
入选标准
- •(1) Signed, written informed consent.
- •(2) Histologically or cytologically confirmed colorectal adenocarcinoma.
- •(3) Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
排除标准
- •(1) Symptomatic brain metastasis.
- •(2) Chronic nausea, vomiting or diarrhea considered to be clinically significant by the Investigator's opinion.
- •(3) Known clinically significant interstitial lung disease or pulmonary fibrosis.
研究者
相似试验
已完成
1 期
A phase 1, open-label, non-randomized, dose-finding, safety and tolerability study of orally administered Teysuno (S1) in combination with Epirubicin and Oxaliplatin in patients with advanced solid tumorsC00-C75Malignant neoplasms, stated or presumed to be primary, of specified sites, except of lymphoid, haematopoietic and related tissueDRKS00004844Disphar International B.V.12
已完成
1 期
A Phase 1, Open-Label, Non-Randomized, Dose-Finding, Safety and Tolerability Study of Orally Administered Teysuno (S-1) in Combination with Epirubicin and Oxaliplatin in Patients with Advanced Solid Tumors: Part 2 – Esophagogastric CancerC00-C75Malignant neoplasms, stated or presumed to be primary, of specified sites, except of lymphoid, haematopoietic and related tissueDRKS00005941Disphar International B.V.12
招募中
2 期
FG001 in subjects with Meningiomas or presumed Low-Grade Gliomas scheduled for neurosurgery.MeningiomaGlioma2024-520426-11-00Copenhagen University Hospital40
进行中（未招募）
1 期
An early stage study looking at how much betrixaban gets into the blood of young people after they take a single capsule, and to see if it is safe to do so.Pediatric patients who are assessed to be at risk for Venous thromboembolism (VTE) but does not require immediate anticoagulant therapy, for example:a. Has previous thrombosis and completed a course of anti-coagulant therapy, and is considered to have a risk for recurrence of VTE, orb. Has any stable disease with a risk for arterial or venous thrombotic disorder, orc. Has any functional CVAD (Central Venous Access Device) in the upper or lower venous system.MedDRA version: 20.0Level: PTClassification code 10053468Term: Anticoagulant therapySystem Organ Class: 10042613 - Surgical and medical proceduresEUCTR2018-002562-40-GBPortola Pharma UK Ltd33
进行中（未招募）
1 期
A study of an oral anticoagulant (Edoxaban) in childreEUCTR2015-005732-18-ITDaiichi Sankyo , Inc.66